Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.

Cancer discovery - 3 Jun 2024

Yaeger Rona, Uboha Nataliya V, Pelster Meredith S, Bekaii-Saab Tanios S, Barve Minal, Saltzman Joel, Sabari Joshua K, Peguero Julio A, Paulson Andrew Scott, Jänne Pasi A, Cruz-Correa Marcia, Anderes Kenna, Velastegui Karen, Yan Xiaohong, Der-Torossian Hirak, Klempner Samuel J, Kopetz Scott E

Abstract excerpt

Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Neoplasm Metastasis

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrimidines

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 38587856
DOI: 10.1158/2159-8290.CD-24-0217
PMCID: PMC11152245

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.PMID 38587856Read ↗

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Semantic proximity Read ↗

Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis.Semantic proximity Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Assessment of KRASG12C inhibitors for colorectal cancerSemantic proximity Read ↗

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.Semantic proximity Read ↗

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C MutationSemantic proximity Read ↗

Adagrasib: First Approval.Semantic proximity Read ↗

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.Semantic proximity Read ↗

Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer.Semantic proximity Read ↗

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.Semantic proximity Read ↗

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.